Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K PaikEnriqueta FelipRemi VeillonHiroshi SakaiAlexis B CortotMarina C GarassinoJulien MazieresSantiago ViteriHelene SenellartJan Van MeerbeeckJo RaskinNiels ReinmuthPierfranco ConteDariusz KowalskiByoung Chul ChoJyoti D PatelLeora HornFrank GriesingerJi-Youn HanYoung-Chul KimGee-Chen ChangChen-Liang TsaiJames C-H YangYuh-Min ChenEgbert F SmitAnthonie J van der WekkenTerufumi KatoDilafruz JuraevaChristopher StrohRolf BrunsJosef StraubAndreas JohneJürgen ScheeleJohn V HeymachXiuning LePublished in: The New England journal of medicine (2020)
Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients. Peripheral edema was the main toxic effect of grade 3 or higher. (Funded by Merck [Darmstadt, Germany]; VISION ClinicalTrials.gov number, NCT02864992.).